European Heart Journal vs Clinical Cancer Research: Which Journal Should You Choose?

EHJ asks whether the paper matters across cardiology. CCR asks whether the paper makes a credible translational oncology argument with visible clinical consequence.

That difference is critical in cardio-oncology and biomarker work.

EHJ's editorial guidance stress general cardiology consequence and field-wide importance. CCR's editorial guidance stress a disciplined translational package where problem, mechanism, and patient-facing meaning all line up. A paper can be biologically sophisticated and still not fit CCR if the translational logic is thin. A paper can be clinically interesting and still not fit EHJ if the cardiology consequence is too narrow.

EHJ wins when the cardiovascular story is central.

That usually means:

• the main consequence is cardiovascular outcomes, risk, or management
• cardiologists are the primary audience
• oncology context matters, but the result still belongs in a broad cardiology conversation
• the paper gets stronger when written as a cardiology paper rather than a translational oncology paper

Examples include:

• treatment-toxicity studies where the practical question is how cardiologists should monitor or manage risk
• cardio-oncology outcome studies with broad cardiovascular consequence
• risk-stratification or imaging papers where the central decision-maker is in cardiology

CCR wins when the oncology story is central.

That includes:

• biomarker papers with real oncology-facing clinical logic
• translational therapy-response work where the mechanism matters to patient management
• oncology studies where cardiovascular findings support a broader cancer-treatment question
• manuscripts where the best readership is translational oncology, not general cardiology

CCR's editorial guidance are especially clear on one point: the clinical implication must be visible in the evidence, not only in the discussion. That's useful here because many cardio-oncology papers look translational at first glance but are still better understood as cardiovascular studies.

CCR's editorial guidance repeatedly warns against mechanistic papers wearing a clinical coat. That matters for crossover work because cardiovascular biomarker or toxicity studies can easily sound more translational-oncology-ready than they really are.

The EHJ material is equally clear that the paper has to matter across cardiology. A cardio-oncology paper can still be too oncology-defined for a flagship general cardiology journal.

That's a meaningful difference from EHJ. If the paper's mechanistic depth is a major strength and the oncology implication is concrete, CCR may be much more natural.

If the cardiovascular management implication is the main event, EHJ becomes more attractive even if the paper sits inside oncology therapy.

• the manuscript is fundamentally cardiovascular
• cardiologists are the main audience
• the core implication is in cardiovascular care, interpretation, or prevention
• the paper reads most convincingly as a cardiology paper

That's the EHJ lane.

• the manuscript is fundamentally translational oncology
• oncology readers are the main audience
• the mechanism-to-clinic link is visible in the main evidence
• the paper reads most convincingly as an oncology paper with translational depth

That's the CCR lane.

These are the hardest category. If the marker is mainly about patient selection, therapy response, or translational oncology decision-making, CCR often wins. If it's mainly about cardiovascular monitoring or cardiovascular risk management, EHJ often wins.

If the question is how oncologists should interpret therapy consequences, CCR can make sense. If the question is how cardiologists should identify, stratify, or manage cardiovascular injury, EHJ becomes more plausible.

These often sound translational, but many are still cleaner cardiology papers because the central question is cardiovascular consequence, not oncology treatment strategy.

This is a reasonable cascade when the first journal was wrong on audience, not on quality.

A paper rejected by EHJ can move to CCR if:

• the manuscript is genuinely oncology-led
• the translational consequence is strong
• the cardiology rejection mainly reflected lack of broad cardiovascular relevance

The reverse route can also happen. A paper rejected by CCR because the clinical oncology implication is too weak may still work at EHJ if the true consequence was cardiovascular all along.

The fact that the cohort is clinically important isn't enough. The cardiovascular consequence must dominate.

CCR's editorial guidance are explicit that the clinical implication has to be visible in the core figures, not invented later in the discussion.

If the paper still lives inside a narrow treatment-toxicity niche, that usually shows.

If the manuscript is elegant biology without enough credible clinical use, it becomes a weak fit.

A strong EHJ first page tells a cardiology editor why the result changes cardiovascular interpretation or management right away.

A strong CCR first page tells an oncology editor why the result changes how a translational oncology problem is understood, and why the clinical consequence is already visible.

If only one of those first pages feels natural, that usually settles the case.

Try finishing one of these sentences:

• "this changes what cardiologists should do or monitor" points toward European Heart Journal
• "this changes how oncologists interpret response, toxicity, or patient selection" points toward Clinical Cancer Research

That's often enough to separate the two.

Authors often treat cardio-oncology work as automatically translational oncology because the setting is cancer therapy. That isn't always true. Some of the best cardio-oncology papers are really cardiovascular management papers with an oncology context.

The opposite mistake also happens. A biomarker or mechanism paper can be dressed up as cardiology because cardiovascular toxicity is present, even though the real audience is oncology. Those are exactly the papers that benefit from a hard audience check before submission.

Send to European Heart Journal first if:

1. the manuscript is fundamentally cardiovascular
2. cardiologists are the practical audience
3. the main consequence is cardiovascular
4. oncology context supports the story, but doesn't define it

Send to Clinical Cancer Research first if:

1. the manuscript is fundamentally translational oncology
2. oncology readers are the practical audience
3. the mechanism-to-clinic argument is central
4. cardiovascular findings are important, but still sit inside an oncology story